This Company Wants to Rewrite the Future of Genetic Disease—Without Crispr Gene Editing

This Company Wants to Rewrite the Future of Genetic Disease—Without Crispr Gene EditingJuly 8, 2020

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

Read more

admin
Author: admin